Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors

International Journal of Pharmaceutics

Volumn 512, Issue 1, 2016, Pages 39-48

  Fang, Tao ^a   Dong, Yuehan ^b   Zhang, Xiaomin ^c   Xie, Ke ^c   Lin, Li ^a   Wang, Hangxiang ^a,c  

^a Jinhua People's Hospital   (China)

^b Zhejiang Economic and Trade Polytechnic ^*  (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Cancer therapy; Drug delivery; Liposome; Prodrug; Supramolecular nanoassembly

Indexed keywords

FIRTECAN; IRINOTECAN; LINOLEIC ACID; PRODRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; LIPOSOME; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; ESTERIFICATION; HCT116 CELL LINE; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIPOPHILICITY; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; RAW 264.7 CELL LINE; SINGLE DRUG DOSE; SUPRAMOLECULAR CHEMISTRY; SUSTAINED DRUG RELEASE; SYSTEMIC CIRCULATION; TUMOR GROWTH; TUMOR XENOGRAFT; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RELEASE; DRUG SCREENING; MACROPHAGE; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; HUMANS; LIPOSOMES; MACROPHAGES; MICE; NANOPARTICLES; PRODRUGS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84987862434     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.08.036     Document Type: Article

References (36)

1. Al-Jamal, W.T., Kostarelos, K., Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Accounts Chem. Res. 44 (2011), 1094–1104.
2. Alferiev, I.S., Iyer, R., Croucher, J.L., Adamo, R.F., Zhang, K., Mangino, J.L., Kolla, V., Fishbein, I., Brodeur, G.M., Levy, R.J., Chorny, M., Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. Biomaterials 51 (2015), 22–29.
3. Allen, T.M., Cullis, P.R., Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65 (2013), 36–48.
4. Bala, V., Rao, S., Boyd, B.J., Prestidge, C.A., Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. J. Controlled Release 172 (2013), 48–61.
5. Buyens, K., De Smedt, S.C., Braeckmans, K., Demeester, J., Peeters, L., van Grunsven, L.A., de Mollerat du Jeu, X., Sawant, R., Torchilin, V., Farkasova, K., Ogris, M., Sanders, N.N., Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J. Controlled Release 158 (2012), 362–370.
6. Hadjidemetriou, M., Al-Ahmady, Z.S., Kostarelos, K., Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. Nanoscale 8 (2016), 6948–6957.
7. Hall, P.A., Levison, D.A., Woods, A.L., Yu, C.C.W., Kellock, D.B., Watkins, J.A., Barnes, D.M., Gillett, C.E., Camplejohn, R., Dover, R., Waseem, N.H., Lane, D.P., Proliferating cell nuclear antigen (Pcna) immunolocalization in paraffin sections – an index of cell-Proliferation with evidence of deregulated expression in some neoplasms. J. Pathol. 162 (1990), 285–294.
8. Hu, C.M., Fang, R.H., Luk, B.T., Zhang, L., Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nanoscale 6 (2014), 65–75.
9. Huang, M., Liu, G., The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett. 135 (1999), 97–105.
10. Huang, Y., Yang, X., Xu, T., Kong, Q., Zhang, Y., Shen, Y., Wei, Y., Wang, G., Chang, K.-J., Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs. Int. J. Oncol. 49 (2016), 153–163.
11. Jiang, C., Wang, H., Zhang, X., Sun, Z., Wang, F., Cheng, J., Xie, H., Yu, B., Zhou, L., Deoxycholic acid-modified chitooligosaccharide/mPEG-PDLLA mixed micelles loaded with paclitaxel for enhanced antitumor efficacy. Int. J. Pharm. 475 (2014), 60–68.
12. Knop, K., Hoogenboom, R., Fischer, D., Schubert, U.S., Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. 49 (2010), 6288–6308.
13. Kolate, A., Baradia, D., Patil, S., Vhora, I., Kore, G., Misra, A., PEG – a versatile conjugating ligand for drugs and drug delivery systems. J. Controlled Release 192 (2014), 67–81.
14. Logue, S.E., Elgendy, M., Martin, S.J., Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. Nat. Protoc. 4 (2009), 1383–1395.
15. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Controlled Release 65 (2000), 271–284.
16. Matsumura, Y., Preclinical and clinical studies of NK012 an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv. Drug Deliv. Rev. 63 (2011), 184–192.
17. Moon, S.J., Govindan, S.V., Cardillo, T.M., D'Souza, C.A., Hansen, H.J., Goldenberg, D.M., Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J. Med. Chem. 51 (2008), 6916–6926.
18. Pinot, M., Vanni, S., Pagnotta, S., Lacas-Gervais, S., Payet, L.A., Ferreira, T., Gautier, R., Goud, B., Antonny, B., Barelli, H., Lipid cell biology: polyunsaturated phospholipids facilitate membrane deformation and fission by endocytic proteins. Science 345 (2014), 693–697.
19. Pizzolato, J.F., Saltz, L.B., The camptothecins. Lancet 361 (2003), 2235–2242.
20. Pommier, Y., Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6 (2006), 789–802.
21. Sayari, E., Dinarvand, M., Amini, M., Azhdarzadeh, M., Mollarazi, E., Ghasemi, Z., Atyabi, F., MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery. Int. J. Pharm. 473 (2014), 304–315.
22. Seeta Rama Raju, G., Benton, L., Pavitra, E., Yu, J.S., Multifunctional nanoparticles: recent progress in cancer therapeutics. Chem. Commun. 51 (2015), 13248–13259.
23. Sengupta, P., Basu, S., Soni, S., Pandey, A., Roy, B., Oh, M.S., Chin, K.T., Paraskar, A.S., Sarangi, S., Connor, Y., Sabbisetti, V.S., Kopparam, J., Kulkarni, A., Muto, K., Amarasiriwardena, C., Jayawardene, I., Lupoli, N., Dinulescu, D.M., Bonventre, J.V., Mashelkar, R.A., Sengupta, S., Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 11294–11299.
24. Sepehri, N., Rouhani, H., Tavassolian, F., Montazeri, H., Khoshayand, M.R., Ghahremani, M.H., Ostad, S.N., Atyabi, F., Dinarvand, R., SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan. Int. J. Pharm. 471 (2014), 485–497.
25. Sharkey, R.M., Govindan, S.V., Cardillo, T.M., Goldenberg, D.M., Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol. Cancer Ther. 11 (2012), 224–234.
26. 14C]CPT-11 in cancer patients. Drug Metab. Dispos. 28 (2000), 423–433.
27. Sun, T., Zhang, Y.S., Pang, B., Hyun, D.C., Yang, M., Xia, Y., Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. 53 (2014), 12320–12364.
28. Termsarasab, U., Yoon, I.-S., Park, J.-H., Moon, H., Cho, H.-J., Kim, D.-D., Polyethylene glycol-modified arachidyl chitosan-based nanoparticles for prolonged blood circulation of doxorubicin. Int. J. Pharm. 464 (2014), 127–134.
29. Venditto, V.J., Simanek, E.E., Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol. Pharm. 7 (2010), 307–349.
30. Wang, H., Chen, W., Xie, H., Wei, X., Yin, S., Zhou, L., Xu, X., Zheng, S., Biocompatible, chimeric peptide-condensed supramolecular nanoparticles for tumor cell-specific siRNA delivery and gene silencing. Chem. Commun. 50 (2014), 7806–7809.
31. Wang, H., Xie, H., Wu, J., Wei, X., Zhou, L., Xu, X., Zheng, S., Structure-based rational design of prodrugs to enable their combination with polymeric nanoparticle delivery platforms for enhanced antitumor efficacy. Angew. Chem. Int. Ed. 53 (2014), 1153–11537.
32. Wang, H., Xie, H., Wang, J., Wu, J., Ma, X., Li, L., Wei, X., Ling, Q., Song, P., Zhou, L., Xu, X., Zheng, S., Self-Assembling prodrugs by precise programming of molecular structures that contribute distinct stability, pharmacokinetics, and antitumor efficacy. Adv. Funct. Mater. 25 (2015), 4956–4965.
33. Xie, H., Xu, X., Chen, J., Li, L., Wang, J., Fang, T., Zhou, L., Wang, H., Zheng, S., Rational design of multifunctional small-molecule prodrugs for simultaneous suppression of cancer cell growth and metastasis in vitro and in vivo. Chem. Commun. 52 (2016), 5601–5604.
34. Yu, B., Hsu, S.H., Zhou, C., Wang, X., Terp, M.C., Wu, Y., Teng, L., Mao, Y., Wang, F., Xue, W., Jacob, S.T., Ghoshal, K., Lee, R.J., Lee, L.J., Lipid nanoparticles for hepatic delivery of small interfering RNA. Biomaterials 33 (2012), 5924–5934.
35. Zhao, H., Rubio, B., Sapra, P., Wu, D.C., Reddy, P., Sai, P., Martinez, A., Gao, Y., Lozanguiez, Y., Longley, C., Greenberger, L.M., Horak, I.D., Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjugate Chem. 19 (2008), 849–859.
36. Zhou, X., Wang, J., Wu, J., Yang, X., Yung, B.C., Lee, L.J., Lee, R.J., Preparation and evaluation of a novel liposomal formulation of cisplatin. Eur. J. Pharm. Sci. 66 (2015), 90–95.